Dyne Therapeutics Inc stock is traded at $17.36, with a volume of 3,209,922. It is down -6.36% in the last 24 hours and up +12.44% over the past month. Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Previous Close:
$18.54
Open:
$18.78
24h Volume:
3,209,922
Relative Volume:
1.31
Market Cap:
$3.24B
Revenue:
-
Net Income/Loss:
-$451.71M
P/E Ratio:
-
EPS:
-$3.23
Net Cash Flow:
-$462.19M
1W Performance:
+1.88%
1M Performance:
+12.44%
6M Performance:
-0.63%
1Y Performance:
-16.94%
1-Day Range:
$17.33$18.78
1-Week Range:
$16.34$19.00
52-Week Range:
$14.00$27.31
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
(781) 786-8230Address
1560 TRAPELO ROAD, WALTHAM, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS